Dishman Carbogen Amcis Limited (NSE:DCAL)
India
· Delayed Price · Currency is INR 247.00
+1.15 (0.47%)
Jun 27, 2025, 3:30 PM IST
Dishman Carbogen Amcis Revenue
In the fiscal year ending March 31, 2025, Dishman Carbogen Amcis had annual revenue of 27.12B INR with 3.66% growth. Dishman Carbogen Amcis had revenue of 7.16B in the quarter ending March 31, 2025, with 9.41% growth.
Revenue
27.12B
Revenue Growth
+3.66%
P/S Ratio
1.43
Revenue / Employee
23.95M
Employees
1,132
Market Cap
38.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 27.12B | 957.30M | 3.66% |
| Mar 31, 2024 | 26.16B | 2.03B | 8.41% |
| Mar 31, 2023 | 24.13B | 2.72B | 12.72% |
| Mar 31, 2022 | 21.41B | 2.29B | 11.96% |
| Mar 31, 2021 | 19.12B | -1.32B | -6.44% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
Dishman Carbogen Amcis News
- 16 days ago - Dishman Carbogen clears US FDA inspection at Naroda facility with no observations - Business Upturn
- 23 days ago - Dishman Carbogen shares in focus after Swiss subsidiary signs CHF 25 million co-investment agreement - Business Upturn
- 5 weeks ago - Dishman Carbogen Amcis shares surge over 11% as company swings to profit in Q4, EBITDA margin doubles - Business Upturn
- 2 months ago - Dishman Carbogen shares surge 5% after arm gets drug manufacturing licence In China - Business Upturn
- 2 months ago - Dishman Carbogen Amcis subsidiary receives drug manufacturing license in China - Business Upturn
- 3 months ago - Dishman Carbogen Amcis shares jump nearly 2% after board approves Rs 50 crore debenture issuance - Business Upturn
- 4 months ago - Q3 2025 Dishman Carbogen Amcis Ltd Earnings Call Transcript - GuruFocus
- 6 months ago - Dishman Carbogen subsidiary successfully completes Swissmedic inspection of its Vionnaz facility - Business Upturn